Denali Therapeutics (DNLI) Earnings Analysis
Denali Therapeutics (DNLI) next reports earnings on 2026-08-10, consensus EPS -0.72 USD. Last quarter (2026-05-07) it beat with EPS -0.69 USD vs -0.73 USD est (+5.5%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -8.21.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DNLI next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.72 USD |
| Revenue estimate | 0.00B |
DNLI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.69 USD | -0.73 USD | +5.5% | Beat |
| 2026-02-26 | -0.73 USD | -0.75 USD | +2.7% | Beat |
| 2025-11-06 | -0.74 USD | -0.76 USD | +2.6% | Beat |
| 2025-08-11 | -0.72 USD | -0.74 USD | +2.7% | Beat |
| 2025-02-27 | -0.67 USD | -0.75 USD | +10.7% | Beat |
| 2024-08-01 | -0.59 USD | -0.68 USD | +13.2% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
DNLI valuation and analyst view
| Trailing P/E | -8.21 |
|---|---|
| Trailing EPS | -2.72195 USD |
| Price / book | 4.76 |
| Dividend yield | 0.00% |
| Market cap | 3.72B |
| Analyst consensus | Buy (19 buy / 0 hold / 0 sell) |
| Avg price target | 32 USD |
Related research pages
Frequently asked questions
When is Denali Therapeutics (DNLI)'s next earnings date?
Denali Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.72 USD and revenue estimate of 0.00B.
Did DNLI beat earnings last quarter?
In its 2026-05-07 report, DNLI posted EPS of -0.69 USD versus a -0.73 USD estimate — a beat of 5.5%.
What is DNLI's earnings track record?
Over the last 6 reported quarters with consensus data, DNLI beat estimates 6 times (100%).
What is DNLI's current P/E ratio and EPS?
DNLI trades at a trailing P/E of -8.21 on trailing EPS of -2.7219525596905023 USD.
What do analysts rate DNLI?
Analyst consensus is "Buy" across 19 ratings (0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 32 USD.